Adaptimmune Therapeutics PLC (ADAPY): Total Assets
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$245.96M
As of 2024-12-31
$130.63M
As of 2025-06-30
-19.4%
3-year compound annual growth
+6.3%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $245.96M | -13.0% | 2025-03-24, Balance as of period end |
| 2023-12-31 | $282.62M | -14.1% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $328.92M | -30.0% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $469.55M | +4.1% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $451.14M | +148.5% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $181.54M | -34.4% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $276.74M | -1.6% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $281.15M | +19.9% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $234.51M | -18.0% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $285.82M | n/a | 2017-03-13, Balance as of period end |
| 2015-06-30 | $300.65M | n/a | 2017-03-13, Balance as of period end |